Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1621 1625
This examiner grants 58% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18015671 | CYCLIC CYANOENONE DERIVATIVES AS MODULATORS OF KEAP1 | Non-Final OA | MERCK SHARP & DOHME LLC |
| 17132937 | DONOR-ACCEPTOR TYPE STABLE THERMALLY ACTIVATED DELAYED FLUORESCENT MATERIALS BASED ON RIGID MOLECULAR STRUCTURE DESIGN | Final Rejection | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY |
| 18264413 | INTRAMOLECULAR CYCLIZATION FOR GENERAL SYNTHESIS OF BICYCLIC ALKYL BIOISOSTERE BORONATES | Non-Final OA | The Board of Regents of The University of Texas System |
| 16885467 | Novel method of treating dystonia | Final Rejection | KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY |
| 18256548 | FLOW SYNTHESIS OF RDX | Non-Final OA | BAE SYSTEMS plc |
| 18287897 | Therapeutics for Hyponatremia and Polycystic Kidney Disease | Non-Final OA | University of Cincinnati |
| 18232230 | CHIRAL PHOSPHORIC ACIDS IMMOBILIZED ON SOLID SUPPORT FOR THE SELECTIVE PROTECTION OF HYDROXYL GROUPS | Non-Final OA | REGENTS OF THE UNIVERSITY OF MICHIGAN |
| 18565484 | METHOD FOR TREATING IDH INHIBITOR-RESISTANT SUBJECTS | Non-Final OA | Eli Lilly and Company |
| 18161380 | Heteroatom-Containing Silane Compound | Non-Final OA | Henkel AG & Co. KGaA |
| 18555058 | COMBINATION THERAPY COMPRISING A PKC INHIBITOR AND A MEK INHIBITOR | Non-Final OA | PFIZER, INC. |
| 18276532 | QUINAZOLIN-4-ONE AND THIENO[2,3-D]PYRIMIDIN-4-ONE INHIBITORS OF ERBB4 (HER4) FOR USE IN THE TREATMENT OF CANCER | Non-Final OA | UNIVERSITEIT ANTWERPEN |
| 17916484 | INDOLE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | Non-Final OA | Vertex Pharmaceuticals Incorporated |
| 18608369 | ARYLAMIDE DERIVATIVE HAVING ANTITUMOR ACTIVITY | Final Rejection | Chugai Seiyaku Kabushiki Kaisha |
| 18407053 | SUBSTITUTED BENZOFURAN, BENZOPYRROLE, BENZOTHIOPHENE, AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS | Final Rejection | BioCryst Pharmaceuticals, Inc |
| 18565704 | PHARMACEUTICAL PREPARATION FOR PREVENTING OR TREATING PULMONARY FIBROSIS | Non-Final OA | J2H BIOTECH INC. |
| 18013696 | OXADIAZOLE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND USE THEREOF | Non-Final OA | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES |
| 18276269 | Tricyclic Derivatives Useful As PARP7 Inhibitors | Non-Final OA | JACOBIO PHARMACEUTICALS CO., LTD. |
| 18276342 | PRODRUG COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | Non-Final OA | MINGHUI PHARMACEUTICAL (SHANGHAI) LIMITED |
| 18264468 | ARYL ETHER COMPOUNDS AS TEAD MODULATORS | Non-Final OA | Merck Sharp& Dohme LLC |
| 18017939 | MANUFACTURING OF DIMERIC CONTRAST AGENTS | Non-Final OA | BRACCO IMAGING S.P.A. |
| 18089265 | PROCESSES AND INTERMEDIATES FOR THE PREPARATIONS OF CARBOPROST AND CARBOPROST TROMETHAMINE, AND CARBOPROST TROMETHAMINE PREPARED THEREFROM | Final Rejection | CHIROGATE INTERNATIONAL INC. |
| 17595761 | TUNGSTEN IMIDO ALKYLIDENE O-BITET AND O-BINOL COMPLEXES AND USE THEREOF IN OLEFIN METATHESIS REACTIONS | Non-Final OA | Verbio SE |
| 17774263 | PROCESS TO CONTINUOUSLY PREPARE A CYCLIC CARBONATE | Final Rejection | NEW GREEN WORLD B.V. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy